# Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

> **NCT04222114** · PHASE3 · UNKNOWN · sponsor: **LintonPharm Co.,Ltd.** · enrollment: 282 (estimated)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Catumaxomab
- **DRUG:** The treatment of investigator choice

## Key facts

- **NCT ID:** NCT04222114
- **Lead sponsor:** LintonPharm Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-06
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 282 (ESTIMATED)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04222114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04222114, "Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04222114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*